Prof. Dr. med. Peter Fasching

Department of Obstetrics and Gynaecology Professur für Translationale Frauenheilkunde und Geburtshilfe

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry (2026) Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma (2026) Zwimpfer TA, Fereday S, Pandey A, Ariyaratne D, Jayawardana MW, Twomey L, Laumont CM, et al. Journal article SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026) Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al. Journal article Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort (2026) Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, et al. Journal article Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial (2026) Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Interactions between genetic and epidemiological factors influencing mammographic density (2026) Suger AH, Chen H, Haas CB, Fan S, Scott CG, Bolla MK, Dennis J, et al. Journal article Effect of postoperative hormonal therapy on pain following endometriosis surgery: a retrospective cohort study (2026) Blum S, Hofbeck L, Sipulina N, Au K, Lotz L, Giacomozzi M, Fasching P, et al. Journal article Physiologically-Based Pharmacokinetics of Ribociclib Drug–Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer (2026) Ji Y, Huth F, Wang C, Schiller H, Combes FP, Crown J, Fasching P, et al. Journal article Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer (2026) Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, et al. Journal article, Review article Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib (2026) Welslau M, Fasching P, Semmler-Lins N, Mueller L, Belleville E, Rieger L, Uhrig S, et al. Journal article